PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Thursday, November 30, 2023: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q3 2023
2023 2022 2023 2022 2022
TSEK July-Sep July-Sep Jan-Sept Jan-Sep Jan-Dec
Profit/loss
Other income 292 493 8.063 3.219 5.183
Profit/loss before -7.537 -14.515 -20.604 -27.496 -34.129
depreciation (EBITDA
Operating profit/loss -7.537 -14.515 -20.604 -27.496 -34.129
befor net financials
Net financials 27 16 36 22 81
Netprofit/loss for -7.510 -14.499 -20.568 -27.474 -34.048
the period
Earnings per share -0,15 -0,51 -0,48 -0,97 -1,09
(SEK)
- September 25, Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections.
- August 28, Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million.
- August 16, Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management.
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11).
- Abstract presented at the 11th Trends in Medical Mycology publicly available
The Financial report can be found on our website: https://biosergen.net/investors/filings